The HIV Epidemic in the USA: Current Trends, 2010



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.


Estimate Annual Percentage Change Urban Poverty Area 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    CDC. HIV surveillance report, 2008. Vol 20. In: Division of HIV/AIDS Prevention NCfHA, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia, editor; 2010.Google Scholar
  2. 2.
    Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619–24.PubMedGoogle Scholar
  3. 3.
    Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977–2006. J Acquir Immune Defic Syndr. 2009;50(2):236–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Trends in HIV/AIDS diagnoses among men who have sex with men – 33 States, 2001–2006. MMWR Morb Mortal Wkly Rep. 2008;57(25):681–6.Google Scholar
  6. 6.
    Hall I, Helms D, Walker F, Belle E. Trends in HIV diagnoses and testing among U.S. adolescent and young adult males XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.Google Scholar
  7. 7.
    Denning P, DiNenno E. Communities in crisis: is there a generalized HIV epidemic in impoverished urban areas of the United States? XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.Google Scholar
  8. 8.
    UNAIDS. 2008 report on the global AIDS epidemic; 2008.Google Scholar
  9. 9.
    CDC. 2010 [cited; Available from: Last accessed August 19, 2010. Slides #14 ands #22.
  10. 10.
    Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009;49(10):1582–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Kousignian I, Abgrall S, Grabar S, et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Clin Infect Dis. 2008;46(2):296–304.PubMedCrossRefGoogle Scholar
  12. 12.
    CDC. Late HIV testing – 34 states, 1996–2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661–5.Google Scholar
  13. 13.
    CDC. Late versus early testing of HIV – 16 Sites, United States, 2000–2003. MMWR Morb Mortal Wkly Rep. 2003;52(25):581–6.Google Scholar
  14. 14.
    CDC. Reported CD4+ T-lymphocyte results for adults and adolescents with HIV/AIDS-33 states, 2005. HIV/AIDS Surveill Suppl Rep. 2005;11(2).Google Scholar
  15. 15.
    Ogbuanu IU, Torres ME, Kettinger L, Albrecht H, Duffus WA. Epidemiological characterization of individuals with newly reported HIV infection: South Carolina, 2004–2005. Am J Public Health. 2007;99 Suppl 1:S111–7.PubMedGoogle Scholar
  16. 16.
    Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis. 2007;45:1369–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Expanded HIV testing and trends in diagnoses of HIV infection – District of Columbia, 2004–2008. MMWR Morb Mortal Wkly Rep. 59(24):737–41Google Scholar
  19. 19.
    Castel A, Samala R, Griffin A, et al. Monitoring the impact of expanded HIV testing in the District of Columbia using population-based HIV/AIDS surveillance data. 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA, 2010.Google Scholar
  20. 20.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009: Department of Health and Human Services.Google Scholar
  21. 21.
    Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMedGoogle Scholar
  23. 23.
    CDC. Persons tested for HIV – United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(31):845–9.Google Scholar
  24. 24.
    The national HIV/AIDS strategy for the United States and the national HIV/AIDS strategy: federal implementation plan. In: House W, editor. Washington, DC; 2010.Google Scholar
  25. 25.
    MacKellar DA, Valleroy LA, Secura GM, et al. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young men who have sex with men - Opportunities for advancing HIV prevention in the third decade of HIV/AIDS. J Acquir Immune Defic Syndr. 2005;38(5):603–14.PubMedCrossRefGoogle Scholar
  26. 26.
    CDC. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men – five U.S. cities, June 2004–April 2005. MMWR Morb Mortal Wkly Rep. 2005;54(24):597–601.Google Scholar
  27. 27.
    CDC. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young black men who have sex with men – six U.S. cities, 1994–1998. MMWR Morb Mortal Wkly Rep. 2002;51(33):733–6.Google Scholar
  28. 28.
    CDC. HIV transmission among black college student and non-student men who have sex with men – North Carolina, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(32):731–4.Google Scholar
  29. 29.
    CDC. HIV transmission among black women – North Carolina, 2004. MMWR Morb Mortal Wkly Rep. 2005;54(4):89–94.Google Scholar
  30. 30.
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46(4):507–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21(6):685–92.PubMedCrossRefGoogle Scholar
  34. 34.
    Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS. 2008;22(1):89–95.PubMedCrossRefGoogle Scholar
  35. 35.
    May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185–97.PubMedCrossRefGoogle Scholar
  36. 36.
    Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Harrison KM, Song RG, Zhang XJ. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Buchacz K, Baker RK, Palella FJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS. 2010;24(10):1549–59.PubMedCrossRefGoogle Scholar
  39. 39.
    Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009;48(5):609–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994–2003 Nationwide Inpatient Sample. Pediatrics. 2007;120(2):e236–e43.PubMedCrossRefGoogle Scholar
  41. 41.
    Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS. 2008;22(11):1345–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4(+) counts greater than 200 cells/mm(3). J Acquir Immune Defic Syndr. 2007;44(2):179–87.PubMedCrossRefGoogle Scholar
  43. 43.
    Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2007;21:2093–100.PubMedCrossRefGoogle Scholar
  44. 44.
    El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4  +  count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRefGoogle Scholar
  45. 45.
    Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Sterne JAC, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63.PubMedCrossRefGoogle Scholar
  47. 47.
    Funk MJ, Fusco JS, Cole SR, et al. HAART initiation and clinical outcomes: insights from the CASCADE cohort of HIV-1 seroconverters on “When to Start.” XVIII International AIDS Conference; 2010; Vienna, Austria; 2010.Google Scholar
  48. 48.
    Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44.PubMedCrossRefGoogle Scholar
  50. 50.
    Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008;47(1):27–35.PubMedCrossRefGoogle Scholar
  51. 51.
    Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;published ahead of print July 26 2010 [DOI:  10.1002/cncr.25311].
  52. 52.
    Uy J, Armon C, Buchacz K, Brooks JT, The HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51(4):450–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370(9603):1923–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-Infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–U29.PubMedGoogle Scholar
  55. 55.
    Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008;5(3):140–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170(15):1337–45.PubMedCrossRefGoogle Scholar
  57. 57.
    Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127(6):1437–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103(3):416–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Spradling PR, Richardson, Buchacz K, Moorman AC, Brooks JT, and the HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepatitis. 2010;(published ahead of print doi: 10.1111/j.1365-2893.2009.01249.x).
  60. 60.
    Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996–2007. J Acquir Immune Defic Syndr. 2010;53(3):388–96.PubMedCrossRefGoogle Scholar
  61. 61.
    Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106.PubMedCrossRefGoogle Scholar
  62. 62.
    Tedaldi EM, Brooks JT, Weidle PJ, et al. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;43(1):35–41.PubMedCrossRefGoogle Scholar
  63. 63.
    Vidrine DJ. Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies. AIDS Educ Prev. 2009;21(3 Suppl):3–13.PubMedCrossRefGoogle Scholar
  64. 64.
    Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. TopHIV Med. 2006;14(5):159–63.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of HIV/AIDS PreventionUS Centers for Disease Control and PreventionAtlantaUSA
  2. 2.Division of HIV/AIDS PreventionNational Center for HIV/AIDS, Viral Hepatitis, and TB Prevention, Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations